Study guide

16.1 Pulmonary Mechanics, Gas Exchange & Acid-Base Regulation

APMLE Part I Basic Sciences Podiatry

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Overview & Lower Extremity Osteology

1.1 APMLE Part I Exam Structure, Policies & Scoring 1.2 Foot Osteology: Tarsals, Metatarsals, Phalanges & Sesamoids 1.3 Leg & Ankle Osteology: Tibia, Fibula & The Ankle Mortise 1.4 Pelvis, Femur & Patella Osteology: Landmarks & Biomechanics

2 Chapter 2: Lower Extremity Arthrology & Ligaments

2.1 Foot Articulations: Subtalar, Midtarsal, Lisfranc & Digital Joints 2.2 Talocrural (Ankle) & Knee Joints: Ligaments & Kinematics 2.3 Hip Joint & Pelvic Articulations: Capsular Structures & Dynamics

3 Chapter 3: Lower Extremity Myology & Compartments

3.1 Anterior & Lateral Compartments of the Leg 3.2 Superficial & Deep Posterior Compartments of the Leg 3.3 Plantar Layers & Intrinsic Musculature of the Foot 3.4 Thigh & Gluteal Musculature: Attachments & Innervations

4 Chapter 4: Lower Extremity Neurovascular & Topographical Anatomy

4.1 Lumbar & Sacral Plexuses, Peripheral Nerves & Dermatomes 4.2 Arterial Network, Venous Drainage & Lymphatics 4.3 Tarsal Tunnel, Femoral Triangle & Topographical Spaces

5 Chapter 5: Microbiology: Bacteriology, Zoonoses & Laboratory Methods

5.1 Gram-Positive Cocci & Bacilli in Podiatric Infections 5.2 Gram-Negative Bacilli & Opportunistic Pathogens 5.3 Anaerobic Pathogens & Diabetic Foot Infections 5.4 Bacterial Structure, Virulence Factors & Sterilization 5.5 Mycobacteria, Spirochetes, Mycoplasma & Zoonotic Infections 5.6 Antimicrobial Resistance, Susceptibility Testing, Specimen Handling & Vaccines

6 Chapter 6: Mycology, Virology, Parasitology & Clinical Immunology

6.1 Mycology: Dermatophytes, Onychomycosis & Systemic Mycoses 6.2 Clinically Relevant Viruses & Parasitic Infections 6.3 Innate & Adaptive Immunity Mechanisms 6.4 Hypersensitivity Reactions, Immunodeficiencies & Autoimmunity 6.5 Transplant & Tumor Immunology and Immunodiagnostic Methods

7 Chapter 7: General & Cellular Pathology

7.1 Cellular Injury, Adaptations & Cell Death Mechanisms 7.2 Acute vs Chronic Inflammation & Tissue Repair 7.3 Hemodynamic Disorders, Thrombosis, Embolism & Shock 7.4 Neoplasia, Oncogenes, Tumor Suppressors & Cutaneous Tumors

8 Chapter 8: Systemic & Podiatric Pathology

8.1 Atherosclerosis, Peripheral Artery Disease & Diabetic Microangiopathy 8.2 Osteoarthritis, Inflammatory Arthritides & Bone Infections 8.3 Neuropathic Disorders, Charcot Neuroarthropathy & Dermatopathology 8.4 Laboratory Diagnostics, Synovial Fluid & Biopsy Interpretation

9 Chapter 9: Organ-System Pathology

9.1 Anemias, Hemoglobinopathies, Leukemias & Immune Disorders 9.2 Cardiac & Pulmonary Pathology 9.3 Renal, Urogenital & Reproductive Pathology 9.4 Gastrointestinal, Hepatobiliary & Endocrine Pathology

10 Chapter 10: General Pharmacology, Autonomic Drugs & Toxicology

10.1 Pharmacokinetics, ADME & Receptor Dynamics 10.2 Cholinergic Agonists & Muscarinic/Nicotinic Antagonists 10.3 Adrenergic Agonists, Sympatholytics & Clinical Applications 10.4 Cardiovascular Pharmacology in Podiatric Patients 10.5 Drug Interactions, Adverse Effects, Pharmacogenomics & Toxicology

11 Chapter 11: Antimicrobial & Podiatric Therapeutics

11.1 Antibacterial Classes, Mechanisms & Resistances 11.2 Antifungal, Antiviral & Antiparasitic Therapeutics 11.3 NSAIDs, Opioids, Corticosteroids & Anti-Gout Agents 11.4 Local & General Anesthetic Pharmacology

12 Chapter 12: Systemic Pharmacology

12.1 Anticonvulsants, Antidepressants, Psychotropics & Skeletal Muscle Relaxants 12.2 Insulin & Noninsulin Glycemic Agents 12.3 Respiratory & Gastrointestinal Agents 12.4 DMARDs, Biologics, Antineoplastics & Immunosuppressants 12.5 Hormone Therapy, Bisphosphonates, Antihistamines, Growth Factors & Complementary Agents

13 Chapter 13: General Anatomy: Systemic Gross Anatomy & Neuroanatomy

13.1 Cranial Nerves, Head & Neck Anatomy 13.2 Thoracic Wall, Tracheobronchial Tree, Lungs & Mediastinum 13.3 Abdominal Wall, GI Viscera, Pelvis & Retroperitoneum 13.4 Vertebral Column, Spinal Cord & Upper Extremity Overview 13.5 Neuroanatomy: CNS Organization, Somatosensory & Motor Pathways

14 Chapter 14: Histology, Integument, Embryology & Genetics

14.1 Microscopic Anatomy: Epithelia, Connective Tissue, Muscle & Nerve 14.2 Integumentary System: Dermis, Appendages, Nail Unit & Cutaneous Receptors 14.3 Embryogenesis, Limb Morphogenesis & Postnatal Development 14.4 Medical Genetics & Structural Alterations in Aging

15 Chapter 15: Cellular, Neuromuscular & Cardiovascular Physiology

15.1 Membrane Potential, Ion Channels & Transport Mechanisms 15.2 Action Potentials, Synaptic Transmission & Muscle Contraction 15.3 Cardiac Electrophysiology, ECG & Hemodynamics 15.4 Blood Pressure Regulation, Poiseuille Law & Capillary Dynamics

16 Chapter 16: Organ-System Physiology: Respiratory, Renal, Endocrine, GI & Blood

16.1 Pulmonary Mechanics, Gas Exchange & Acid-Base Regulation 16.2 Renal Filtration, Tubular Transport & Fluid/Acid-Base Balance 16.3 Endocrine Regulation, Reproductive Hormones, Calcium & Bone 16.4 Gastrointestinal & Hepatobiliary Physiology 16.5 Hematology: Erythropoiesis, Leukocytes, Platelets & Coagulation 16.6 Exercise Physiology, Thermoregulation & Bone Mechanobiology

17 Chapter 17: Biochemistry: Proteins, Enzymes, Carbohydrates & Signaling

17.1 Amino Acid Chemistry, Protein Structure & Enzyme Kinetics 17.2 Glycolysis, Gluconeogenesis, Glycogen Metabolism & TCA Cycle 17.3 Electron Transport Chain, ATP Synthesis & Metabolic Inborn Errors 17.4 Hormones, Receptors, Second Messengers & Signal Transduction

18 Chapter 18: Biochemistry: Lipids, Molecular Genetics, Blood Chemistry & Nutrition

18.1 Fatty Acid Oxidation, Ketogenesis, Cholesterol & Lipoproteins 18.2 Nucleotide Metabolism, DNA Replication, Transcription, Translation & Repair 18.3 Vitamins, Micronutrients & Inborn Errors of Metabolism 18.4 Blood Chemistry: Heme Metabolism, Hemoglobin & Plasma Proteins 18.5 Nutrition: Energy Balance, Glycemic Index, Fed-Fast Cycle & Free Radicals

16.1 Pulmonary Mechanics, Gas Exchange & Acid-Base Regulation

Key Takeaways Explain This Topic AI

Static lung volumes include Tidal Volume (500 mL), Inspiratory Reserve Volume (~3000 mL), Expiratory Reserve Volume (~1100 mL), and Residual Volume (~1200 mL); Residual Volume and capacities containing it (FRC, TLC) cannot be measured by standard spirometry and require helium dilution or body plethysmography.

Functional Residual Capacity (FRC = ERV + RV) represents the resting equilibrium lung volume where inward elastic recoil of the lungs exactly balances outward elastic recoil of the chest wall, resulting in zero alveolar pressure and a resting intrapleural pressure of approximately -5 cmH2O.

Obstructive ventilatory defects (asthma, COPD, bronchiectasis) are characterized by an FEV1/FVC ratio < 0.70, increased airway resistance, dynamic expiratory airway compression, and pulmonary hyperinflation with elevated TLC, FRC, and RV; restrictive defects (pulmonary fibrosis, chest wall deformity, neuromuscular weakness) maintain a normal or elevated FEV1/FVC ratio (≥ 0.70) with a reduced TLC (< 80% predicted).

Pulmonary surfactant, synthesized by Type II pneumocytes and composed primarily of dipalmitoylphosphatidylcholine (DPPC), lowers alveolar surface tension according to the Law of Laplace (P = 2T/r), dynamically reducing collapsing pressure in small alveoli to prevent end-expiratory atelectasis and equalize alveolar pressures; an amniotic lecithin-to-sphingomyelin (L/S) ratio > 2.0 confirms fetal lung maturity.

The oxygen-hemoglobin dissociation curve exhibits a sigmoidal profile with a P50 of 27 mmHg; rightward shifts (decreased O2 affinity, enhanced tissue delivery) are triggered by acidosis (Bohr effect), hypercapnia, elevated 2,3-BPG, and fever (CADET: CO2, Acid, 2,3-DPG, Exercise, Temperature), whereas carbon monoxide produces a profound leftward shift and functional anemia without altering dissolved arterial PaO2.

Last updated: October 2026

16.1 Pulmonary Mechanics, Gas Exchange & Acid-Base Regulation

Independent Study Guide Notice: Independent study guide by ExamFinch. This educational resource is developed independently by ExamFinch and is not sponsored, endorsed, or affiliated with the National Board of Podiatric Medical Examiners (NBPME) or Meazure Learning.

Introduction to Pulmonary Physiology

Respiration encompasses the integrated physical and chemical processes by which oxygen is extracted from the atmosphere and transported to metabolizing tissues, while carbon dioxide—the terminal end product of cellular aerobic metabolism—is eliminated to maintain systemic acid-base equilibrium. For podiatric physicians, a rigorous mastery of pulmonary mechanics, gas diffusion, ventilation-perfusion matching, and hemoglobin transport is vital. Perioperative risk assessment, general anesthesia induction, postoperative atelectasis, deep vein thrombosis with acute pulmonary embolism, and acid-base disturbances in diabetic ketoacidosis all center directly upon these physiological foundations.

Lung Volumes & Capacities

Pulmonary ventilation is quantified through four discrete non-overlapping lung volumes and four composite lung capacities (combinations of two or more volumes): Spirometric Lung Volumes & Capacities

  • LUNG VOLUME (mL)
  • 6000 ┌────────────────────────────────────────────────────────┐ ◄─── TOTAL LUNG
  • │ │ CAPACITY (TLC)
  • │ Inspiratory Reserve Volume (IRV) │ (~6000 mL)
  • │ (~3000 mL) │
  • 3000 ├────────────────────────────┬───────────────────────────┤ ◄─── INSPIRATORY
  • │ Tidal Volume (TV, 500 mL)│ Vital Capacity (VC) │ CAPACITY (IC)
  • 2500 ├────────────────────────────┤ (~4800 mL) │ (~3500 mL)
  • │ Expiratory Reserve │ │
  • │ Volume (ERV) │ │
  • 1200 ├─────────(~1100 mL)─────────┴───────────────────────────┤ ◄─── FUNCTIONAL RESIDUAL
  • │ │ CAPACITY (FRC)
  • │ Residual Volume (RV) │ (~2300 mL)
  • 0 └─────────(~1200 mL)─────────────────────────────────────┘
  • *(RV, FRC, and TLC CANNOT be measured by standard spirometry)*
  • The Four Primary Lung Volumes

Tidal Volume (TV or V T V_T V T ​ , ~500 mL): The volume of air inhaled or exhaled with each normal, quiet, spontaneous breath at rest. Of this 500 mL, approximately 350 mL reaches the gas-exchanging alveoli ( alveolar ventilation ), while roughly 150 mL remains in the non-perfused conducting airways ( anatomical dead space , V D V_D V D ​ ).

Inspiratory Reserve Volume (IRV, ~3000 mL): The maximal volume of air that can be forcefully inhaled above and beyond the normal tidal volume peak.

Expiratory Reserve Volume (ERV, ~1100 mL): The maximal volume of air that can be forcefully exhaled at the end of a normal tidal expiration.

Residual Volume (RV, ~1200 mL): The volume of air remaining inside the lungs following a maximal, forceful exhalation. This volume cannot be voluntarily expelled under physiological conditions because the surrounding thoracic cage and small-airway closure prevent total alveolar collapse.

The Four Composite Lung Capacities

Inspiratory Capacity (IC, ~3500 mL): IC = TV + IRV \text{IC} = \text{TV} + \text{IRV} IC = TV + IRV . The maximal volume of air that can be inspired following a normal tidal expiration.

Vital Capacity (VC, ~4800 mL): VC = TV + IRV + ERV \text{VC} = \text{TV} + \text{IRV} + \text{ERV} VC = TV + IRV + ERV . The total volume of gas that can be maximally exhaled following a maximal inhalation. Also termed Forced Vital Capacity (FVC) when exhaled forcefully and rapidly.

Functional Residual Capacity (FRC, ~2300 mL): FRC = ERV + RV \text{FRC} = \text{ERV} + \text{RV} FRC = ERV + RV . The volume of gas remaining in the lungs at the end of a normal, passive tidal exhalation.

Biomechanical Significance of FRC: FRC represents the resting equilibrium volume of the respiratory system . At FRC, the inward elastic recoil of the lungs is exactly equal and opposite to the outward elastic recoil of the thoracic wall. Consequently, the net distending pressure across the respiratory system is zero, alveolar pressure equals atmospheric pressure ( 0 cmH 2 O 0 \text{ cmH}_2\text{O} 0 cmH 2 ​ O ), and the respiratory muscles are completely relaxed. Intrapleural pressure ( P i p P_{ip} P i p ​ ) at FRC is negative (approximately − 5 cmH 2 O -5 \text{ cmH}_2\text{O} − 5 cmH 2 ​ O ).

Total Lung Capacity (TLC, ~6000 mL): TLC = TV + IRV + ERV + RV = VC + RV = IC + FRC \text{TLC} = \text{TV} + \text{IRV} + \text{ERV} + \text{RV} = \text{VC} + \text{RV} = \text{IC} + \text{FRC} TLC = TV + IRV + ERV + RV = VC + RV = IC + FRC . The total volume of gas contained within the lungs following a maximal inspiratory effort.

Volume / Capacity Formula Approximate Normal Value Measurable by Standard Spirometry? Clinical / Board Significance

Tidal Volume (TV) Base measurement ~500 mL (7 mL/kg) Yes Normal resting breath; 30% occupies anatomical dead space

Inspiratory Reserve Volume (IRV) Base measurement ~3000 mL Yes Driven by diaphragm and external intercostals

Expiratory Reserve Volume (ERV) Base measurement ~1100 mL Yes Driven by active exhalation (rectus abdominis, internal intercostals)

Residual Volume (RV) Base measurement ~1200 mL NO Prevents complete alveolar collapse; elevated in COPD

Inspiratory Capacity (IC) TV + IRV \text{TV} + \text{IRV} TV + IRV ~3500 mL Yes Peak volume inspired from resting end-expiratory baseline

Vital Capacity (VC / FVC) TV + IRV + ERV \text{TV} + \text{IRV} + \text{ERV} TV + IRV + ERV ~4800 mL Yes Reflects respiratory muscle strength and total usable lung volume

Functional Residual Capacity (FRC) ERV + RV \text{ERV} + \text{RV} ERV + RV ~2300 mL NO Equilibrium point where lung inward recoil = chest outward recoil

Total Lung Capacity (TLC) VC + RV \text{VC} + \text{RV} VC + RV ~6000 mL NO Definitive marker of restriction ( < 80 % <80\% < 80% ) vs hyperinflation ( > 120 % >120\% > 120% )

Important

The Spirometry Blind Spot: Standard spirometry measures only the volume of gas that moves into or out of the mouth. Because Residual Volume (RV) never leaves the thoracic cavity during any voluntary maneuver, RV cannot be measured by spirometry . Consequently, any composite capacity that includes RV—specifically Functional Residual Capacity (FRC) and Total Lung Capacity (TLC) —also cannot be determined by spirometry alone .

To measure RV, FRC, and TLC, specialized pulmonary diagnostic techniques are mandatory:

Helium Dilution Technique: A closed-circuit spirometer containing a known fraction and volume of insoluble helium ( C 1 × V 1 = C 2 × [ V 1 + FRC ] C_1 \times V_1 = C_2 \times [V_1 + \text{FRC}] C 1 ​ × V 1 ​ = C 2 ​ × [ V 1 ​ + FRC ] ). Helium equilibrates only with ventilated airways; it underestimates FRC in severe obstructive lung disease with non-communicating bullae.

Body Plethysmography ("Body Box"): Based on Boyle's Law ( P 1 V 1 = P 2 V 2 P_1 V_1 = P_2 V_2 P 1 ​ V 1 ​ = P 2 ​ V 2 ​ at constant temperature). Measures total compressible intrathoracic gas volume (including non-ventilated bullae and trapped air), providing the most accurate assessment of true FRC and TLC in advanced COPD.

Spirometry & Ventilatory Defect Classification

Dynamic spirometry evaluates airflow limitation by recording forced exhalation against time from maximal inspiration (TLC) to maximal exhalation (RV). The three core parameters evaluated are:

Forced Vital Capacity (FVC): Total volume exhaled forcefully.

Forced Expiratory Volume in 1 Second ( F E V 1 FEV_1 FE V 1 ​ ): Volume exhaled during the first second of the forced maneuver.

F E V 1 / F V C FEV_1 / FVC FE V 1 ​ / F V C Ratio: Fraction of total capacity exhaled in the initial second (normal in young adults is 0.75 – 0.85 0.75\text{--}0.85 0.75 – 0.85 , or > 0.70 >0.70 > 0.70 across all ages). Dynamic Spirometry Curves (Volume vs. Time)

  • VOLUME (L)
  • 5.0 ┌────────────────────────────────────────────────────────┐ ◄── Normal FVC (5.0 L)
  • │ ──────────────────────────────┤ ◄── Restrictive FVC (3.2 L)
  • 4.0 ├───────────/────────────── │ ◄── Normal FEV1 (4.0 L)
  • │ / │ Normal FEV1/FVC = 0.80
  • 3.0 ├─────────/ │ ◄── Obstructive FVC (3.5 L)
  • │ / /──────────────────────────────────────────┤ ◄── Restrictive FEV1 (2.7 L)
  • 2.0 ├───────/ / │ Restrictive FEV1/FVC = 0.84
  • │ / / │
  • 1.0 ├─────/ / │ ◄── Obstructive FEV1 (1.4 L)
  • │ / / │ Obstructive FEV1/FVC = 0.40
  • 0 └────┴────┴──────────────────────────────────────────────┘
  • 0 1 2 3 4 5 6 7 8 Time (seconds)
  • ▲
  • FEV1 Measurement Point (t = 1.0 s)
  • Obstructive vs. Restrictive Ventilatory Patterns Flow-Volume Loop Morphology
  • EXPIRATION (Flow L/s)
  • 8 ┌ /\
  • │ / \
  • 6 │ / \ NORMAL
  • │ / \
  • 4 │ /\ / \ OBSTRUCTIVE
  • │ / \ / \ - "Scooped out" expiratory limb
  • 2 │ / \___/ \ - Shifted to left (high volumes)
  • 0 └───────┴────────────────┴───
  • │ \ /\ /
  • 2 │ \ / \ / RESTRICTIVE
  • 4 │ \/ \___________/ - Narrow "witch's hat"
  • └────────────────────────────- Normal/elevated FEV1/FVC
  • 8 7 6 5 4 3 2 1 0 LUNG VOLUME (L)
  • High Volumes (TLC) Low Volumes (RV)

Obstructive Lung Diseases (Airway Resistance Elevation):

Prototypical Etiologies: Asthma, Chronic Obstructive Pulmonary Disease (COPD: Chronic Bronchitis and Emphysema), Bronchiectasis, Cystic Fibrosis.

Pathophysiology: Chronic inflammation, mucosal edema, smooth muscle hypertrophy, or loss of radial traction due to alveolar septal destruction (emphysema) narrows airways. Dynamic airway compression occurs during forced expiration, causing marked flow limitation at low lung volumes.

Spirometric Hallmarks:

F E V 1 / F V C < 0.70 FEV_1 / FVC < 0.70 FE V 1 ​ / F V C < 0.70 (Definitive diagnostic criterion).

F E V 1 FEV_1 FE V 1 ​ is markedly reduced; FVC is normal or mildly reduced.

Flow-volume loop shows a pathognomonic coved or "scooped-out" expiratory limb .

Air Trapping and Hyperinflation: Residual Volume (RV) and Functional Residual Capacity (FRC) are dramatically elevated. Total Lung Capacity (TLC) is increased ( > 120 % >120\% > 120% of predicted).

Bronchodilator Reversibility Testing: Administration of an inhaled short-acting β 2 \beta_2 β 2 ​ -agonist (e.g., albuterol) producing an increase in F E V 1 FEV_1 FE V 1 ​ of > 12 % >12\% > 12% AND > 200 mL >200 \text{ mL} > 200 mL demonstrates reversible bronchospasm, confirming the diagnosis of asthma rather than fixed COPD.

Restrictive Lung Diseases (Lung Compliance or Chest Wall Limitation):

Intrinsic (Parenchymal) Etiologies: Idiopathic Pulmonary Fibrosis (IPF), sarcoidosis, pneumoconioses (asbestosis, silicosis), radiation fibrosis, and drug-induced pulmonary toxicity ( bleomycin, amiodarone, busulfan, methotrexate ).

Extrinsic (Chest Wall & Neuromuscular) Etiologies: Severe kyphoscoliosis, ankylosing spondylitis, pectus excavatum, morbid obesity-hypoventilation syndrome (Pickwickian syndrome), Amyotrophic Lateral Sclerosis (ALS), Myasthenia Gravis, Guillain-Barré syndrome, and phrenic nerve palsy.

Pathophysiology: Parenchymal deposition of rigid collagen or mechanical chest wall restriction prevents normal lung expansion, drastically reducing overall pulmonary compliance.

Spirometric Hallmarks:

F E V 1 / F V C FEV_1 / FVC FE V 1 ​ / F V C ratio is normal or ELEVATED ( > 0.70 >0.70 > 0.70 , typically > 0.80 – 0.85 >0.80\text{--}0.85 > 0.80 – 0.85 ). Because the stiff radial fibrotic parenchyma pulls small airways open (increased radial traction), expiratory flow rates remain exceptionally high relative to the tiny lung volume.

Both F E V 1 FEV_1 FE V 1 ​ and FVC are reduced in equal proportion.

Total Lung Capacity (TLC) < 80 % < 80\% < 80% of predicted (Definitive gold standard for restrictive diagnosis).

Flow-volume loop appears as a miniaturized, narrow, symmetrical "witch's hat" shifted to the right toward lower absolute lung volumes.

Diagnostic Parameter Normal Baseline Obstructive Defect (COPD, Asthma) Restrictive Defect (Fibrosis, Scoliosis)

F E V 1 / F V C FEV_1 / FVC FE V 1 ​ / F V C Ratio 0.75 – 0.85 0.75\text{--}0.85 0.75 – 0.85 ( > 0.70 >0.70 > 0.70 ) Decreased ( < 0.70 <0.70 < 0.70 ) Normal or Increased ( > 0.70 – 0.85 >0.70\text{--}0.85 > 0.70 – 0.85 )

F E V 1 FEV_1 FE V 1 ​ ≥ 80 % \ge 80\% ≥ 80% predicted Markedly Decreased ( < 80 % <80\% < 80% ) Decreased ( < 80 % <80\% < 80% )

FVC ≥ 80 % \ge 80\% ≥ 80% predicted Normal or Mildly Decreased Markedly Decreased ( < 80 % <80\% < 80% )

Total Lung Capacity (TLC) 80 – 120 % 80\text{--}120\% 80 – 120% predicted Increased ( > 120 % >120\% > 120% , Hyperinflation) Decreased ( < 80 % <80\% < 80% , Restrictive Hallmark)

Residual Volume (RV) 80 – 120 % 80\text{--}120\% 80 – 120% predicted Markedly Increased (Air Trapping) Decreased ( < 80 % <80\% < 80% )

FRC Normal baseline Elevated Decreased

DLCO (Diffusion Capacity) Normal Decreased in emphysema; Normal in asthma Decreased in IPF; Normal in chest wall defects

  • Pulmonary Mechanics & Surfactant Biophysics
  • Pressures Governing Respiration & Transpulmonary Pressure

Air moves into and out of the pulmonary tree down hydrostatic pressure gradients established by active respiratory muscle contraction:

Atmospheric Pressure ( P a t m P_{atm} P a t m ​ ): Conventionally set to 0 cmH 2 O 0 \text{ cmH}_2\text{O} 0 cmH 2 ​ O as the reference baseline.

Alveolar Pressure ( P a l v P_{alv} P a l v ​ ): Pressure within the pulmonary alveoli. During inspiration, P a l v P_{alv} P a l v ​ drops to − 1 cmH 2 O -1 \text{ cmH}_2\text{O} − 1 cmH 2 ​ O , drawing air inward. At end-inspiration and end-expiration, airflow ceases and P a l v = 0 cmH 2 O P_{alv} = 0 \text{ cmH}_2\text{O} P a l v ​ = 0 cmH 2 ​ O . During active expiration, P a l v P_{alv} P a l v ​ rises to + 1 cmH 2 O +1 \text{ cmH}_2\text{O} + 1 cmH 2 ​ O .

Intrapleural Pressure ( P i p P_{ip} P i p ​ ): Hydrostatic fluid pressure within the potential space between the parietal and visceral pleurae. Under physiological resting conditions, P i p P_{ip} P i p ​ is always negative (subatmospheric), ranging from − 5 cmH 2 O -5 \text{ cmH}_2\text{O} − 5 cmH 2 ​ O at FRC to − 8 cmH 2 O -8 \text{ cmH}_2\text{O} − 8 cmH 2 ​ O at end-inspiration .

Transpulmonary Pressure ( P t p P_{tp} P tp ​ ): The distending pressure across the alveolar wall: P t p = P a l v − P i p P_{tp} = P_{alv} - P_{ip} P tp ​ = P a l v ​ − P i p ​ Under all resting physiological conditions, P t p P_{tp} P tp ​ is positive ( 0 − [ − 5 ] = + 5 cmH 2 O 0 - [-5] = +5 \text{ cmH}_2\text{O} 0 − [ − 5 ] = + 5 cmH 2 ​ O ), providing the outward mechanical tension that maintains alveolar patency and prevents atelectasis.

Note

Pneumothorax Biophysics: If the chest wall or visceral pleura is punctured (e.g., trauma, rupture of an apical subpleural bleb in tall, thin young men), atmospheric air rushes into the intrapleural space down its pressure gradient until P i p P_{ip} P i p ​ equilibrates with atmospheric pressure ( P i p = 0 cmH 2 O P_{ip} = 0 \text{ cmH}_2\text{O} P i p ​ = 0 cmH 2 ​ O ). As a result, transpulmonary pressure drops to zero ( P t p = P a l v − P i p = 0 − 0 = 0 P_{tp} = P_{alv} - P_{ip} = 0 - 0 = 0 P tp ​ = P a l v ​ − P i p ​ = 0 − 0 = 0 ). Bereft of distending pressure, the lung's unopposed inward elastic recoil causes immediate parenchymal collapse , while the unopposed outward recoil of the thoracic cage causes the ipsilateral hemithorax to spring outward .

Pulmonary Compliance & Elastic Recoil

Compliance ( C = Δ V Δ P C = \frac{\Delta V}{\Delta P} C = Δ P Δ V ​ ) quantifies the distensibility or ease with which the respiratory structures expand under a given change in transpulmonary distending pressure:

High Pulmonary Compliance: Seen in pulmonary emphysema . Enzymatic destruction of alveolar elastin by elastase (uninhibited in α 1 \alpha_1 α 1 ​ -antitrypsin deficiency or triggered by cigarette smoke) destroys alveolar septa. The lungs lose elastic recoil, become hypercompliant ("floppy"), inflate with minimal effort, but fail to recoil during passive exhalation, causing severe dynamic air trapping.

Low Pulmonary Compliance: Seen in pulmonary fibrosis, acute respiratory distress syndrome (ARDS), pulmonary edema, and neonatal respiratory distress syndrome . The lungs become exceptionally stiff and non-compliant, requiring massive muscular effort and high transpulmonary pressures to achieve minimal tidal volume expansion.

Pulmonary Surfactant & The Law of Laplace

The physical stability of spherical alveoli lined by a thin aqueous fluid layer is governed by the Law of Laplace for a sphere: P = 2 T r P = \frac{2T}{r} P = r 2 T ​ Where:

P P P is the inward collapsing (distending) pressure exerted on the bubble/alveolus.

T T T is the surface tension generated at the air-liquid interface (dynes/cm).

r r r is the alveolar radius. Law of Laplace & Surfactant Action

  • WITHOUT SURFACTANT: (Uniform Surface Tension T1 = T2)
  • P = 2T / r
  • Alveolus A (Small, r = 1) Alveolus B (Large, r = 2)
  • Collapsing P = 2(T) / 1 = 2P Collapsing P = 2(T) / 2 = 1P
  • ┌────────┐ ┌────────────────┐
  • │ High P │ ═════════════════════► │ Low Pressure │
  • └────────┘ Air empties into └────────────────┘
  • COLLAPSE / larger alveolus OVERDISTENSION
  • ATELECTASIS
  • ─────────────────────────────────────────────────────────────────
  • WITH SURFACTANT: (Dynamic Surface Tension Reduction)
  • Surfactant is more concentrated in smaller alveoli (T1 << T2)
  • Alveolus A (Small, r = 1) Alveolus B (Large, r = 2)
  • Surface tension lowered to 0.5T Surface tension remains 1.0T
  • P = 2(0.5T) / 1 = 1P P = 2(1.0T) / 2 = 1P
  • ┌────────┐ ┌────────────────┐
  • │ P = 1P │ ◄────────────────────► │ P = 1P │
  • └────────┘ Pressures Equalized └────────────────┘
  • STABLE (No Collapse) STABLE (No Overdistension)

Biophysical Dilemma: If surface tension ( T T T ) were constant across all alveoli, smaller alveoli (small radius r r r ) would generate a substantially higher collapsing pressure than larger alveoli. Down this pressure gradient, air would empty from small alveoli into adjoining large alveoli, causing catastrophic widespread alveolar collapse ( microatelectasis ) and concurrent localized overdistension.

Surfactant Solution: Pulmonary surfactant is synthesized and stored within lamellar bodies by Type II pneumocytes (cuboidal cells comprising ~5% of alveolar surface area that also serve as regenerative stem cells for Type I pneumocytes). The primary surface-active component is dipalmitoylphosphatidylcholine (DPPC / lecithin) , a zwitterionic phospholipid assisted by surfactant apoproteins (SP-A, SP-B, SP-C, SP-D).

Mechanism: Surfactant molecules intersperse among water molecules at the alveolar air-liquid interface, shielding water dipoles and drastically reducing surface tension. Crucially, as an alveolus deflates during exhalation, surfactant molecules are crowded into a tighter packing density, reducing surface tension proportionally more in small alveoli than in large alveoli . This equalizes collapsing pressures across alveoli of varying diameters, prevents end-expiratory atelectasis, and markedly increases overall pulmonary compliance.

Important

Neonatal Respiratory Distress Syndrome (NRDS / Hyaline Membrane Disease): Type II pneumocytes begin synthesizing surfactant around gestational week 24 to 26, but clinically mature surfactant levels are typically not achieved until gestational week 35 . Premature infants born before week 32 to 34 exhibit severe surfactant deficiency, leading to high alveolar surface tension, diffuse microatelectasis, severe intrapulmonary shunting, refractory hypoxemia, and secondary formation of proteinaceous intra-alveolar hyaline membranes .

Amniocentesis Assessment: Assessed via the Lecithin-to-Sphingomyelin (L/S) ratio in amniotic fluid. Sphingomyelin levels remain constant throughout pregnancy, while lecithin (DPPC) surges after week 32. An L / S ratio > 2.0 L/S \text{ ratio} > 2.0 L / S ratio > 2.0 confirms fetal lung maturity ; an L / S ratio < 1.5 L/S \text{ ratio} < 1.5 L / S ratio < 1.5 indicates extreme risk of NRDS.

Prevention & Therapy: Mothers in preterm labor before 34 weeks receive intramuscular betamethasone or dexamethasone (antenatal corticosteroids accelerate fetal Type II pneumocyte maturation and surfactant gene transcription). Postnatally, affected premature neonates receive exogenous intratracheal surfactant replacement and CPAP.

  • Alveolar Gas Exchange & Ventilation-Perfusion Dynamics
  • The Alveolar Gas Equation

The partial pressure of oxygen within the alveoli ( P A O 2 P_A O_2 P A ​ O 2 ​ ) determines the driving gradient for diffusion into pulmonary capillary blood. It is calculated via the Alveolar Gas Equation : P A O 2 = P I O 2 − P a C O 2 R P_A O_2 = P_I O_2 - \frac{P_a CO_2}{R} P A ​ O 2 ​ = P I ​ O 2 ​ − R P a ​ C O 2 ​ ​ P I O 2 = F I O 2 × ( P a t m − P H 2 O ) P_I O_2 = F_I O_2 \times (P_{atm} - P_{H_2O}) P I ​ O 2 ​ = F I ​ O 2 ​ × ( P a t m ​ − P H 2 ​ O ​ ) Where:

F I O 2 F_I O_2 F I ​ O 2 ​ is the fraction of inspired oxygen ( 0.21 0.21 0.21 on room air).

P a t m P_{atm} P a t m ​ is barometric pressure ( 760 mmHg 760 \text{ mmHg} 760 mmHg at sea level).

P H 2 O P_{H_2O} P H 2 ​ O ​ is the water vapor pressure at normal body temperature ( 47 mmHg 47 \text{ mmHg} 47 mmHg at 37 ∘ C 37^\circ\text{C} 3 7 ∘ C ).

Thus, inspired oxygen pressure on room air is: P I O 2 = 0.21 × ( 760 − 47 ) ≈ 150 mmHg P_I O_2 = 0.21 \times (760 - 47) \approx 150 \text{ mmHg} P I ​ O 2 ​ = 0.21 × ( 760 − 47 ) ≈ 150 mmHg .

P a C O 2 P_a CO_2 P a ​ C O 2 ​ is arterial carbon dioxide partial pressure (normal: 40 mmHg 40 \text{ mmHg} 40 mmHg ).

R R R is the respiratory exchange ratio (metabolic carbon dioxide production divided by oxygen consumption; typically 0.8 0.8 0.8 on an average diet).

Substituting standard sea-level values: P A O 2 = 150 − P a C O 2 0.8 = 150 − ( 1.25 × P a C O 2 ) P_A O_2 = 150 - \frac{P_a CO_2}{0.8} = 150 - (1.25 \times P_a CO_2) P A ​ O 2 ​ = 150 − 0.8 P a ​ C O 2 ​ ​ = 150 − ( 1.25 × P a ​ C O 2 ​ ) At a normal P a C O 2 P_a CO_2 P a ​ C O 2 ​ of 40 mmHg 40 \text{ mmHg} 40 mmHg : P A O 2 = 150 − ( 1.25 × 40 ) = 150 − 50 = 100 mmHg P_A O_2 = 150 - (1.25 \times 40) = 150 - 50 = 100 \text{ mmHg} P A ​ O 2 ​ = 150 − ( 1.25 × 40 ) = 150 − 50 = 100 mmHg

The Alveolar-Arterial (A-a) Gradient

The A-a gradient ( P A O 2 − P a O 2 P_A O_2 - P_a O_2 P A ​ O 2 ​ − P a ​ O 2 ​ ) evaluates the functional integrity of the alveolar-capillary gas-exchange membrane:

Normal A-a Gradient: < 10 – 15 mmHg < 10\text{--}15 \text{ mmHg} < 10 – 15 mmHg in healthy young adults breathing room air. It increases progressively with age (estimated clinically as Age 4 + 4 \frac{\text{Age}}{4} + 4 4 Age ​ + 4 ). A small normal gradient persists due to physiological right-to-left shunts (thebesian veins draining into the left ventricle and bronchial veins draining into pulmonary veins).

Hypoxemia with NORMAL A-a Gradient ( < 15 mmHg < 15 \text{ mmHg} < 15 mmHg ):

Alveolar Hypoventilation: Respiratory depression from opioid/benzodiazepine overdose, acute brainstem injury, ALS, Guillain-Barré, or flail chest. P a C O 2 P_a CO_2 P a ​ C O 2 ​ rises, which automatically lowers P A O 2 P_A O_2 P A ​ O 2 ​ according to the alveolar gas equation. Because the alveolar-capillary barrier is completely normal, arterial P a O 2 P_a O_2 P a ​ O 2 ​ drops in exact lockstep with P A O 2 P_A O_2 P A ​ O 2 ​ , maintaining a normal A-a gradient.

High Altitude: Reduced barometric pressure ( P a t m P_{atm} P a t m ​ ) lowers inspired P I O 2 P_I O_2 P I ​ O 2 ​ , reducing P A O 2 P_A O_2 P A ​ O 2 ​ and P a O 2 P_a O_2 P a ​ O 2 ​ equally.

Hypoxemia with ELEVATED A-a Gradient ( > 15 – 20 mmHg > 15\text{--}20 \text{ mmHg} > 15 – 20 mmHg ): Signifies intrinsic pulmonary parenchymal or vascular pathology that impairs gas exchange:

Ventilation-Perfusion ( V / Q V/Q V / Q ) Mismatch: COPD, asthma, localized pulmonary edema, pulmonary embolism.

Anatomical or Physiological Right-to-Left Shunt: Cyanotic congenital heart defects (Tetralogy of Fallot), pulmonary arteriovenous malformations (AVMs), complete alveolar collapse (dense lobar pneumonia, ARDS, massive atelectasis).

Diffusion Limitation: Interstitial pulmonary fibrosis, sarcoidosis, asbestosis.

Regional Ventilation-Perfusion ( V / Q V/Q V / Q ) Ratios

In an upright individual, gravity exerts a profound hydrostatic influence on both pulmonary ventilation ( V V V ) and pulmonary capillary perfusion ( Q Q Q ):

Apex (Top of Lung): Both ventilation and perfusion are low compared to the base, but perfusion is disproportionately lower due to low hydrostatic pulmonary arterial pressure. Consequently, the V / Q ratio V/Q \text{ ratio} V / Q ratio is high (~3.0) . Because ventilation greatly exceeds perfusion, local alveolar P A O 2 P_A O_2 P A ​ O 2 ​ is high ( 130 mmHg 130 \text{ mmHg} 130 mmHg ) and P A C O 2 P_A CO_2 P A ​ C O 2 ​ is low ( 28 mmHg 28 \text{ mmHg} 28 mmHg ). Clinical Board Correlation: High apical oxygen tension provides the optimal metabolic environment for the reactivation of obligate aerobic Mycobacterium tuberculosis , which characteristically forms cavitary lesions in the lung apices.

Base (Bottom of Lung): Gravity pulls blood and lung tissue downward, making both ventilation and perfusion highest at the lung bases. However, perfusion increases far more than ventilation. Consequently, the V / Q ratio V/Q \text{ ratio} V / Q ratio is low (~0.6) . Alveolar P A O 2 P_A O_2 P A ​ O 2 ​ is lower ( 89 mmHg 89 \text{ mmHg} 89 mmHg ) and P A C O 2 P_A CO_2 P A ​ C O 2 ​ is higher ( 42 mmHg 42 \text{ mmHg} 42 mmHg ).

Average Global V / Q V/Q V / Q : Across the entire lung, resting alveolar ventilation is ~4.0 L/min and pulmonary blood flow is ~5.0 L/min, yielding an average global V / Q ≈ 0.8 V/Q \approx 0.8 V / Q ≈ 0.8 . Ventilation / Perfusion Spectrum

  • SHUNT (V/Q = 0) NORMAL (V/Q = 0.8) DEAD SPACE (V/Q = ∞)
  • ┌─────────────────────┐ ┌─────────────────────┐ ┌─────────────────────┐
  • │ Perfused, Unventilated│ │ Matched Gas Exchange│ │ Ventilated, Unperfused│
  • │ (Dense consolidation,│ │ PAO2 = 100 mmHg │ │ (Pulmonary Embolism)│
  • │ lobar atelectasis) │ │ PaCO2 = 40 mmHg │ │ PAO2 = 150 mmHg │
  • │ │ │ │ │ PACO2 = 0 mmHg │
  • └──────────┬──────────┘ └──────────┬──────────┘ └──────────┬──────────┘
  • │ │ │
  • ▼ ▼ ▼
  • Supplemental 100% O2 Supplemental 100% O2 Alveoli act like
  • DOES NOT CORRECT readily corrects conducting airways;
  • hypoxemia (PO2 stays low) hypoxemia no gas exchange

Shunt ( V / Q = 0 V/Q = 0 V / Q = 0 ): Perfusion occurs in the complete absence of ventilation (e.g., foreign body obstruction, dense consolidation, ARDS). Mixed venous blood bypasses ventilated alveoli and enters systemic circulation completely deoxygenated. Hallmark: Supplemental 100% oxygen ( F I O 2 = 1.0 F_I O_2 = 1.0 F I ​ O 2 ​ = 1.0 ) CANNOT correct hypoxemia caused by a true shunt because the administered oxygen cannot reach the perfused alveoli.

Dead Space ( V / Q = ∞ V/Q = \infty V / Q = ∞ ): Ventilation occurs in the complete absence of capillary perfusion (e.g., acute pulmonary embolism occluding a pulmonary arterial branch). Alveolar gas composition matches inspired air ( P A O 2 = 150 mmHg , P A C O 2 = 0 mmHg P_A O_2 = 150 \text{ mmHg}, P_A CO_2 = 0 \text{ mmHg} P A ​ O 2 ​ = 150 mmHg , P A ​ C O 2 ​ = 0 mmHg ).

  • Oxygen-Hemoglobin Dissociation & Gas Transport
  • Cooperativity & The Sigmoidal Curve

Oxygen is transported in the blood in two forms: dissolved in plasma (a tiny fraction: 0.003 mL O 2 / 100 mL blood / mmHg P a O 2 0.003 \text{ mL } O_2 / 100 \text{ mL blood / mmHg } P_a O_2 0.003 mL O 2 ​ /100 mL blood / mmHg P a ​ O 2 ​ ) and reversibly bound to the iron ( F e 2 + Fe^{2+} F e 2 + ) atoms of hemoglobin ( H b Hb H b ). Hemoglobin is a tetramer of two α \alpha α and two β \beta β subunits, each containing a heme prosthetic group. It exhibits positive cooperativity : binding of an initial O 2 O_2 O 2 ​ molecule to one subunit induces a conformational transition from the deoxygenated, low-affinity Tense (T) state to the oxygenated, high-affinity Relaxed (R) state , progressively facilitating the binding of subsequent O 2 O_2 O 2 ​ molecules. This produces the classic sigmoidal (S-shaped) oxygen-hemoglobin dissociation curve .

P 50 P_{50} P 50 ​ : The partial pressure of oxygen at which hemoglobin is 50% saturated with O 2 O_2 O 2 ​ . Normal adult human P 50 P_{50} P 50 ​ is 27 mmHg 27 \text{ mmHg} 27 mmHg . An increase in P 50 P_{50} P 50 ​ indicates a rightward shift (reduced affinity), while a decrease indicates a leftward shift (increased affinity). Oxygen-Hemoglobin Dissociation Curve

  • HEMOGLOBIN SATURATION (%)
  • 100 ┌──────────────────────────────────── Left Shift (Tighter binding)

│ .-─''''─-.

80 ├─────────────────────────.-' / . '-. Normal Curve (P50 = 27)

│ .-' / . '─.

60 ├────────────────────.' / . '-. Right Shift (Unloading)

│ .' / . '─.

50 ├────────────────-┼────────/───┼───────────────────'-.

│ .' / . '-.

40 ├──────────────' / . '-.

│ / / . '-.

  • 20 ├───────────.' / . \
  • │ / / . \
  • 0 └─────────┴──────────┴─────────┴───────────┴───────────┴─────────┴──
  • 0 10 20 27 40 60 100
  • ▲
  • PO2 (mmHg) at Normal P50

Allosteric Effectors: Shifting the Dissociation Curve Allosteric Regulators of Oxygen Affinity (CADET Mnemonic)

  • RIGHTWARD SHIFT (Reduced Affinity -> Unloading) ══► CADET Face RIGHT
  • C: Carbon Dioxide (elevated PaCO2)
  • A: Acidosis (elevated [H+], decreased pH) [Bohr Effect]
  • D: 2,3-DPG / 2,3-BPG (elevated levels in RBCs)
  • E: Exercise (muscle produces heat, acid, CO2)
  • T: Temperature (fever, elevated core temperature)
  • ─────────────────────────────────────────────────────────────────
  • LEFTWARD SHIFT (Increased Affinity -> Tighter Binding)
  • Decreased PaCO2 (hypocapnia)
  • Alkalosis (decreased [H+], elevated pH)
  • Decreased 2,3-BPG levels (banked stored blood)
  • Hypothermia (decreased body temperature)
  • Fetal Hemoglobin (HbF, α2γ2; lacks 2,3-BPG binding site)
  • Carboxyhemoglobin (Carbon monoxide poisoning)
  • Methemoglobin (Fe3+ oxidized heme)

Rightward Shift (Enhanced Tissue Oxygen Unloading; Elevated P 50 P_{50} P 50 ​ ):

Occurs in metabolically active, exercising, or hypoxic tissues where oxygen demand is high.

The Bohr Effect: Hydrogen ions bind specific allosteric amino acid residues on deoxyhemoglobin, stabilizing salt bridges that lock hemoglobin in the low-affinity T-state, promoting immediate unloading of oxygen to respiring cells.

2,3-Bisphosphoglycerate (2,3-BPG / DPG): Produced in erythrocytes via the Rapoport-Luebering glycolytic shunt. A single molecule of 2,3-BPG binds into the central cavity of the deoxyhemoglobin tetramer, stabilizing the T-state. 2,3-BPG synthesis increases in response to chronic hypoxia, high altitude, and chronic anemia.

Leftward Shift (Inhibited Tissue Unloading; Decreased P 50 P_{50} P 50 ​ ):

Occurs in the pulmonary capillaries (cooling, C O 2 CO_2 C O 2 ​ elimination, rising pH) to maximize oxygen loading from alveoli.

Pathologically impairs peripheral oxygen delivery: hemoglobin binds oxygen so avidly that it refuses to release it to metabolizing tissues, precipitating tissue cellular hypoxia despite high arterial saturation.

Fetal Hemoglobin (HbF, α 2 γ 2 \alpha_2\gamma_2 α 2 ​ γ 2 ​ ): Adult hemoglobin (HbA, α 2 β 2 \alpha_2\beta_2 α 2 ​ β 2 ​ ) binds 2,3-BPG via positively charged histidine residues in its β \beta β -chains. The γ \gamma γ -chains of HbF replace histidine with neutral serine, drastically diminishing 2,3-BPG binding affinity. Consequently, HbF possesses a substantially higher affinity for oxygen than maternal HbA ( P 50 ≈ 19 mmHg P_{50} \approx 19 \text{ mmHg} P 50 ​ ≈ 19 mmHg ), enabling the fetus to extract oxygen across the placenta.

Carbon Monoxide, Methemoglobinemia & Cyanide

Feature Carbon Monoxide (CO) Poisoning Methemoglobinemia Cyanide Toxicity

Etiology Inhaling combustion exhaust, house fires, faulty space heaters Dapsone, topical benzocaine/lidocaine sprays, nitrites/nitrates, sulfonamides Structure fires (burning synthetic polymers/wool), industrial chemicals, nitroprusside

Biochemical Mechanism CO binds F e 2 + Fe^{2+} F e 2 + with 200--250x higher affinity than O 2 O_2 O 2 ​ ; induces extreme leftward shift of remaining sites Heme iron oxidized from ferrous ( F e 2 + Fe^{2+} F e 2 + ) to ferric ( F e 3 + Fe^{3+} F e 3 + ); cannot bind O 2 O_2 O 2 ​ ; remaining F e 2 + Fe^{2+} F e 2 + shifted left Inhibits mitochondrial Cytochrome c Oxidase (Complex IV) ; halts aerobic ATP generation

  • Arterial P a O 2 P_a O_2 P a ​ O 2 ​ NORMAL (dissolved O 2 O_2 O 2 ​ in plasma is unaffected) NORMAL NORMAL
  • O 2 O_2 O 2 ​ Content ( C a O 2 C_a O_2 C a ​ O 2 ​ ) Markedly Decreased Decreased Normal

Pulse Oximetry ( S p O 2 Sp O_2 Sp O 2 ​ ) Falsely NORMAL (cannot distinguish carboxyHb from oxyHb) Plateaus at ~85% (absorbs equally at 660 & 940 nm) Normal

Physical Hallmarks Headache, nausea, "cherry-red" flushed skin (rare/postmortem) Cyanosis unresponsive to O 2 O_2 O 2 ​ ; chocolate-brown blood Severe lactic acidosis, bright red venous blood, almond odor

Definitive Treatment 100% Normobaric or Hyperbaric Oxygen (shortens t 1 / 2 t_{1/2} t 1/2 ​ from 300 to 90/30 min) Intravenous Methylene Blue (reduces F e 3 + Fe^{3+} F e 3 + via NADPH metHb reductase); Vitamin C Hydroxocobalamin (binds CN to form cyanocobalamin); Sodium thiosulfate/nitrites